TrialJournal for immunotherapy of cancer2026

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Rana R McKay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.